Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant

This study has been completed.
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Yi-Bin A. Chen, MD, Massachusetts General Hospital Identifier:
First received: July 19, 2011
Last updated: October 3, 2016
Last verified: October 2016